“Development of new targeted therapies for leukemia: pathway to the clinic.”
Dr. Jolanta Grembecka, Associate Professor, Proteomics and Small Molecule Experimental Pathology, University of Michigan
Thursday, March 16, 2017 | 12:00pm – 1:00pm | R3 C203
Dr. Jolanta Grembecka received her Ph.D. in Chemistry at Wroclaw University of Technology, Poland. She completed two postdoctoral trainings at the University of Virginia, in structural biology and drug discovery, before she got promoted to Research Assistant Professor. In 2009, Dr. Grembecka joined the Department of Pathology at the University of Michigan where she is now an Associate Professor. Dr. Grembecka’s research has focused on the development of small molecule inhibitors of proteins involved in oncogenesis, with a particular focus on leukemia related proteins. Dr. Grembecka is a co-author on 60 scientific papers in top ranked journals, including Cancer Cell, Science, Nature Chemical Biology, Leukemia, and an inventor on 6 patents. She is regularly invited as a speaker at national and international symposia related to her field. She serves as a reviewer on different grant review committees, including the Career Development Program from the Leukemia and Lymphoma Society.
Recent work from Dr. Grembecka’s laboratory has been dedicated to identify and develop small molecules targeting the protein-protein interaction between menin and MLL as a new targeted therapy for acute leukemia patients with translocations of the MLL gene. Her laboratory has developed the first small molecule inhibitors of the menin-MLL interaction, which they successfully optimized resulting in very potent compounds that are currently being translated to clinical studies. Her laboratory is also pursuing development of new targeted therapies for hematologic and solid cancers by blocking novel epigenetic targets, including histone methyltransferases and ubiquitin ligases.
For more information, contact Crissy Quenichet email@example.com.
Originally published at ctsi.nd.edu.